Cargando…

Long-Acting Injectable Antiretroviral Agents for HIV Treatment and Prevention

Current oral antiretroviral agents provide highly effective treatment for patients infected with human immunodeficiency virus (HIV), and can be used as pre-exposure prophylaxis (PrEP) to prevent new HIV infections. Several single-tablet regimens with excellent antiviral efficacy have dramatically im...

Descripción completa

Detalles Bibliográficos
Autor principal:	Kim, Yeon-Sook
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Society of Infectious Diseases; Korean Society for Antimicrobial Therapy; The Korean Society for AIDS 2021
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8731252/ https://www.ncbi.nlm.nih.gov/pubmed/34979604 http://dx.doi.org/10.3947/ic.2021.0136

Ejemplares similares

Long-acting injectable antiretrovirals for HIV treatment and prevention
por: Spreen, William R., et al.
Publicado: (2013)

Injectable long acting antiretroviral for HIV treatment and prevention: perspectives of potential users
por: Slama, Laurence, et al.
Publicado: (2023)

Long-acting injectable antiretroviral therapy: will it change the future of HIV treatment?
por: Brizzi, Marisa, et al.
Publicado: (2023)

Long-acting antiretrovirals: a new era for the management and prevention of HIV infection
por: Thoueille, Paul, et al.
Publicado: (2021)

The only way is up: priorities for implementing long-acting antiretrovirals for HIV prevention and treatment
por: Castor, Delivette, et al.
Publicado: (2020)

Safety and Efficacy of Long-Acting Injectable Agents for HIV-1: Systematic Review and Meta-Analysis
por: Wang, Wenjing, et al.
Publicado: (2023)

A new paradigm for antiretroviral delivery: long-acting cabotegravir and rilpivirine for the treatment and prevention of HIV
por: Bares, Sara H., et al.
Publicado: (2022)

Assessing readiness to implement long-acting injectable HIV antiretroviral therapy: provider and staff perspectives
por: Koester, Kimberly A., et al.
Publicado: (2023)

Long-acting antiviral agents for HIV treatment
por: Margolis, David A., et al.
Publicado: (2015)

1600. Long-Acting Antiretroviral Injectable: Who Would Benefit?
por: Pogorzelski, Karolina, et al.
Publicado: (2023)

Examining adherence barriers among women with HIV to tailor outreach for long-acting injectable antiretroviral therapy
por: Benning, Lorie, et al.
Publicado: (2020)

Acceptability and feasibility of long-acting injectable antiretroviral therapy for HIV-infected persons who inject drugs in Vietnam: A qualitative study
por: Rutstein, Sarah E., et al.
Publicado: (2022)

HIV Treatment as Prevention: Natural Experiments Highlight Limits of Antiretroviral Treatment as HIV Prevention
por: Wilson, David P.
Publicado: (2012)

Raltegravir in combination with other antiretroviral agents for the treatment of HIV infection
por: Chirch, Lisa M, et al.
Publicado: (2010)

2499. Perceptions of and Preferences for Oral or Long-Acting Injectable Antiretroviral Treatment Regimens in the United States and Canada
por: Garris, Cindy, et al.
Publicado: (2019)

Long-Acting HIV Treatment and Prevention: Closer to the Threshold
por: Barnhart, Matthew
Publicado: (2017)

Safety and efficacy of long-acting injectable cabotegravir as preexposure prophylaxis to prevent HIV acquisition
por: Fonner, Virginia A., et al.
Publicado: (2023)

Evaluating cabotegravir/rilpivirine long-acting, injectable in the treatment of HIV infection: emerging data and therapeutic potential
por: Fernandez, Cristina, et al.
Publicado: (2019)

Perceptions of Long-Acting Injectable Antiretroviral Treatment Regimens in a United States Urban Academic Medical Center
por: Koren, David E., et al.
Publicado: (2020)

Long Acting Injectable Antipsychotics in the Treatment of Schizophrenia and Bipolar Disorder
por: DEVRİMCİ ÖZGÜVEN, Halise, et al.
Publicado: (2021)

Factors Associated with Preferences for Long-Acting Injectable Antiretroviral Therapy Among Adolescents and Young People Living with HIV in South Africa
por: Toska, Elona, et al.
Publicado: (2023)

First Demonstration Project of Long-Acting Injectable Antiretroviral Therapy for Persons With and Without Detectable Human Immunodeficiency Virus (HIV) Viremia in an Urban HIV Clinic
por: Christopoulos, Katerina A, et al.
Publicado: (2022)

Long‐acting injectable cabotegravir: implementation science needed to advance this additional HIV prevention choice
por: Schmidt, Heather‐Marie Ann, et al.
Publicado: (2022)

Pharmacogenomics of drug transporters for antiretroviral long-acting pre-exposure prophylaxis for HIV
por: Zondo, Nomusa M., et al.
Publicado: (2022)

Patient and Health Care Provider Perspectives on Long Acting Injectable Antipsychotics in Schizophrenia and the Introduction of Olanzapine Long-Acting Injection
por: Wehring, Heidi J., et al.
Publicado: (2011)

Practical Guidance for the Use of Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia
por: Riboldi, Ilaria, et al.
Publicado: (2022)

Patient and Healthcare Professional Preferences for Characteristics of Long-Acting Injectable Antipsychotic Agents for the Treatment of Schizophrenia
por: Robinson, Delbert G., et al.
Publicado: (2023)

2496. Qualitative Thematic Analysis of Social Media Data to Assess Perceptions of Daily Oral and Long-Acting Injectable Antiretroviral Treatment among People Living with HIV
por: Matza, Louis S, et al.
Publicado: (2019)

The Promise of Improved Adherence With Long-Acting Antiretroviral Therapy: What Are the Data?
por: Scarsi, Kimberly K., et al.
Publicado: (2021)

Perspectives on long-acting injectable HIV antiretroviral therapy at an alternative care site: a qualitative study of people with HIV experiencing substance use and/or housing instability
por: Fletcher, Laura, et al.
Publicado: (2023)

Long-acting or extended-release antiretroviral products for HIV treatment and prevention in infants, children, adolescents, and pregnant and breastfeeding women: knowledge gaps and research priorities
por: Nachman, Sharon, et al.
Publicado: (2019)

Securing accelerated access to long‐acting injectable cabotegravir for HIV prevention in low‐ and middle‐income countries
por: Jenkins, Sarah Y., et al.
Publicado: (2023)

New Antiretroviral Treatment for HIV
por: Badowski, Melissa E., et al.
Publicado: (2016)

Combination treatment with risperidone long-acting injection and psychoeducational approaches for preventing relapse in schizophrenia
por: Zhao, Yueren, et al.
Publicado: (2013)

HIV Treatment as Prevention: Modelling the Cost of Antiretroviral Treatment—State of the Art and Future Directions
por: Meyer-Rath, Gesine, et al.
Publicado: (2012)

A critical appraisal of paliperidone long-acting injection in the treatment of schizoaffective disorder
por: Chue, Pierre, et al.
Publicado: (2016)

Realizing the promise of long-acting antiretroviral treatment strategies for individuals with HIV and adherence challenges: an illustrative case series
por: Kilcrease, Christin, et al.
Publicado: (2022)

Long-acting Injectable Antipsychotics in First-episode Schizophrenia
por: Jeong, Hyun-Ghang, et al.
Publicado: (2013)

Patient perspectives in the development and use of long-acting antipsychotics in schizophrenia: focus on olanzapine long-acting injection
por: Citrome, Leslie
Publicado: (2009)

Ultra-long-acting removable drug delivery system for HIV treatment and prevention
por: Kovarova, Martina, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ab66dd3f171opj28589lmpec4p